Quelltext anzeigen

Du bist nicht berechtigt, die Seite zu bearbeiten. Grund:

Du kannst den Quelltext dieser Seite betrachten und kopieren:

Published oct 29, 2021 sacubitril (entresta)inhibits trpm7 my personal target of interest. -essential papers- {{tp|p=C8565918|t=2021. Focus on pharmacogenomics phytonutrient-drug interactions and COVID-19 vaccines: Perspectives on ADRs ADEs and SEDs.|pdf=|usr=}} {{tp|p=C8444447|t=2021. Physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patients.|pdf=|usr=}} {{tp|p=C8317454|t=2021. Artificial intelligence-driven drug repurposing and structural biology for SARS-CoV-2.|pdf=|usr=}} {{tp|p=C7890335|t=2021. The spectrum of COVID-19 in complex adult congenital heart disease: A case series.|pdf=|usr=}} {{tp|p=C8326513|t=2021. Receptors | Angiotensin Receptors.|pdf=|usr=}} {{tp|p=C8091429|t=2021. PREDICTORS OF LIKELIHOOD OF TAKING SACUBITRIL-VALSARTAN AND A HYPOTHETICAL MEDICATION FOR COVID-19.|pdf=|usr=}} {{tp|p=32921718|t=2020. How to overcome cardiovascular challenges in COVID-19 patients: a guide for common practice.|pdf=|usr=}} {{tp|p=31399990|t=2019. Antifibrotic Roles of RAAS Blockers: Update.|pdf=|usr=}} {{tp|p=32502882|t=2020. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.|pdf=|usr=}} {{tp|p=33827074|t=2021. Outcomes of Hospitalized COVID-19 Patients Receiving Renin Angiotensin System Blockers and Calcium Channel Blockers.|pdf=|usr=}} {{tp|p=32639866|t=2020. Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury.|pdf=|usr=}} {{tp|p=32370986|t=2020. Renin-angiotensin-aldosterone system and COVID-19 infection.|pdf=|usr=}} {{tp|p=34066998|t=2021. Cnicin as an Anti-SARS-CoV-2: An Integrated In Silico and In Vitro Approach for the Rapid Identification of Potential COVID-19 Therapeutics.|pdf=|usr=}} {{tp|p=34134920|t=2021. Vasoactive Peptides: Their Role in COVID-19 Pathogenesis and Potential Use as Biomarkers and Therapeutic Targets.|pdf=|usr=}} {{tp|p=32470547|t=2020. Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost.|pdf=|usr=}} {{tp|p=34715788|t=2021. Cardiogenic shock complicating multisystem inflammatory syndrome following COVID-19 infection: a case report.|pdf=|usr=}} {{tp|p=33795925|t=2020. Neprilysin Inhibitors and Angiotensin(1-7) in COVID-19.|pdf=|usr=}} {{tp|p=32998363|t=2020. Angiotensin Inhibition, TGF-beta and EMT in Cancer.|pdf=|usr=}} {{tp|p=32671601|t=2021. Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective.|pdf=|usr=}} {{tp|p=33926209|t=2021. CaMKII Serine 280 O-GlcNAcylation Links Diabetic Hyperglycemia to Proarrhythmia.|pdf=|usr=}} {{tp|p=32537662|t=2020. Impaired cardiac function is associated with mortality in patients with acute COVID-19 infection.|pdf=|usr=}} {{tp|p=34055238|t=2021. Prediction of repurposed drugs for Coronaviruses using artificial intelligence and machine learning.|pdf=|usr=}} {{tp|p=33631357|t=2021. RAMIC: Design of a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of ramipril in patients with COVID-19.|pdf=|usr=}} {{tp|p=33005549|t=2020. COVID-19 Presenting as Major Thromboembolic Events: Virchow's Triad Revisited and Clinical Considerations of Therapeutic Anticoagulation.|pdf=|usr=}} {{tp|p=33200501|t=2021. COVID-19 fatality prediction in people with diabetes and prediabetes using a simple score upon hospital admission.|pdf=|usr=}} {{tp|p=32420637|t=2020. Repurposing current therapeutics for treating COVID-19: A vital role of prescription records data mining.|pdf=|usr=}} {{tp|p=33084001|t=2020. The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets.|pdf=|usr=}} {{tp|p=34754175|t=2021. What will be the role of molnupiravir in the treatment of COVID-19 infection?|pdf=|usr=}} {{tp|p=34792677|t=2021. Risk of drug-induced cardiac arrhythmia during COVID-19 therapeutic treatment.|pdf=|usr=}} {{tp|p=32955172|t=2020. Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?|pdf=|usr=}} {{tp|p=33498096|t=2021. Worsening of heart failure by coronavirus disease 2019 is associated with high mortality.|pdf=|usr=}} {{tp|p=33026699|t=2020. Being responsible for someone else: a shared duty for parents and heart failure specialists during the COVID-19 pandemic.|pdf=|usr=}} {{tp|p=34031865|t=2021. Protecting older patients with cardiovascular diseases from COVID-19 complications using current medications.|pdf=|usr=}} {{tp|p=33659979|t=2021. A randomized trial supports the recommendation to continue treatment with ACEi or ARBs during hospitalization for COVID-19.|pdf=|usr=}} {{tp|p=32498078|t=2020. Renin-angiotensin system inhibitors in the COVID-19 pandemic: consequences of antihypertensive drugs.|pdf=|usr=}} {{tp|p=32369103|t=2020. Sacubitril/valsartan in COVID-19 patients: the need for trials.|pdf=|usr=}} {{tp|p=32282032|t=2020. Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients.|pdf=|usr=}} {{tp|p=32859477|t=2020. Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study.|pdf=|usr=}} {{tp|p=32926917|t=2020. Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2.|pdf=|usr=}} {{tp|p=33011243|t=2020. New putative insights into neprilysin (NEP)-dependent pharmacotherapeutic role of roflumilast in treating COVID-19.|pdf=|usr=}} {{tp|p=33628162|t=2021. Insights into the actions of angiotensin-1 receptor (AT1R) inverse agonists: Perspectives and implications in COVID-19 treatment.|pdf=|usr=}} {{tp|p=34195234|t=2021. Myocardial Work Efficiency, A Novel Measure of Myocardial Dysfunction, Is Reduced in COVID-19 Patients and Associated With In-Hospital Mortality.|pdf=|usr=}} {{tp|p=34778271|t=2021. Sacubitril Ameliorates Cardiac Fibrosis Through Inhibiting TRPM7 Channel.|pdf=|usr=}} {{tp|p=34603042|t=2021. Sacubitril/Valsartan Alleviates Experimental Autoimmune Myocarditis by Inhibiting Th17 Cell Differentiation Independently of the NLRP3 Inflammasome Pathway.|pdf=|usr=}} {{tp|p=34539406|t=2021. Lcz696 Alleviates Myocardial Fibrosis After Myocardial Infarction Through the sFRP-1/Wnt/beta-Catenin Signaling Pathway.|pdf=|usr=}} {{tp|p=34135764|t=2021. Protective Effects of Sacubitril/Valsartan on Cardiac Fibrosis and Function in Rats With Experimental Myocardial Infarction Involves Inhibition of Collagen Synthesis by Myocardial Fibroblasts Through Downregulating TGF-beta1/Smads Pathway.|pdf=|usr=}} {{tp|p=33519461|t=2020. Sacubitril/Valsartan Reduces Fibrosis and Alleviates High-Salt Diet-Induced HFpEF in Rats.|pdf=|usr=}} {{tp|p=32564908|t=2020. COVID-19 - Does This Disease Kill Due to Imbalance of the Renin Angiotensin System (RAS) Caused by Genetic and Gender Differences in the Response to Viral ACE 2 Attack?|pdf=|usr=}} {{tp|p=33688410|t=2020. COVID-19 and Heart Failure: The Big Challenge.|pdf=|usr=}} {{tp|p=34739696|t=2021. A short focus, azithromycin in the treatment of respiratory viral infection COVID-19: efficacy or inefficacy?|pdf=|usr=}} {{tp|p=32405088|t=2020. Cardiological society of India position statement on COVID-19 and heart failure.|pdf=|usr=}} {{tp|p=33932192|t=2021. Brief review of the mRNA vaccines COVID-19.|pdf=|usr=}} {{tp|p=33221168|t=2021. Potential role of interferons in treating COVID-19 patients.|pdf=|usr=}} {{tp|p=33083516|t=2020. The influence of ACE inhibitors and ARBs on hospital length of stay and survival in people with COVID-19.|pdf=|usr=}} {{tp|p=32875060|t=2020. Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers and the risk of COVID-19 infection or severe disease: Systematic review and meta-analysis.|pdf=|usr=}} {{tp|p=32724831|t=2020. COVID-19 cardiovascular epidemiology, cellular pathogenesis, clinical manifestations and management.|pdf=|usr=}} {{tp|p=33145103|t=2020. Renin-Angiotensin System Inhibitors in COVID-19: Current Concepts.|pdf=|usr=}} {{tp|p=33809971|t=2021. Renin-Angiotensin-Aldosterone System: Friend or Foe-The Matter of Balance. Insight on History, Therapeutic Implications and COVID-19 Interactions.|pdf=|usr=}} {{tp|p=33203141|t=2020. The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19.|pdf=|usr=}} {{tp|p=33888248|t=2021. Another Nudge to Overcome the Treatment-Risk Paradox in Blood Pressure Management.|pdf=|usr=}} {{tp|p=29042424|t=2017. Angiotensin II Receptor-Neprilysin Inhibitor Sacubitril/Valsartan Improves Endothelial Dysfunction in Spontaneously Hypertensive Rats.|pdf=|usr=}} {{tp|p=32597315|t=2021. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease.|pdf=|usr=}} {{tp|p=32694923|t=2020. Blood Targets of Adjuvant Drugs Against COVID19.|pdf=|usr=}} {{tp|p=32282502|t=2020. Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19).|pdf=|usr=}} {{tp|p=32301766|t=2020. Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2.|pdf=|usr=}} {{tp|p=32937008|t=2020. Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol.|pdf=|usr=}} {{tp|p=33490288|t=2021. The Cytokine Profiles and Immune Response Are Increased in COVID-19 Patients with Type 2 Diabetes Mellitus.|pdf=|usr=}} {{tp|p=34429797|t=2021. COVID-19 Pneumonia Precipitating Acute Anterior Wall Myocardial Infarction With Large Left Ventricular Apical Thrombus.|pdf=|usr=}} {{tp|p=33384064|t=2021. Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19.|pdf=|usr=}} {{tp|p=32265149|t=2020. End-Stage Heart Failure With COVID-19: Strong Evidence of Myocardial Injury by 2019-nCoV.|pdf=|usr=}} {{tp|p=32493638|t=2020. Considerations for Heart Failure Care During the COVID-19 Pandemic.|pdf=|usr=}} {{tp|p=33464336|t=2021. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.|pdf=|usr=}} {{tp|p=32558877|t=2020. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.|pdf=|usr=}} {{tp|p=33342753|t=2021. Renin-angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis.|pdf=|usr=}} {{tp|p=33422263|t=2021. Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.|pdf=|usr=}} {{tp|p=33607159|t=2021. COVID-19, cytokines, inflammation, and spices: How are they related?|pdf=|usr=}} {{tp|p=32991879|t=2020. Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19.|pdf=|usr=}} {{tp|p=32471831|t=2020. Reply to Siniorakis et al., "COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure".|pdf=|usr=}} {{tp|p=32444383|t=2020. COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure.|pdf=|usr=}} {{tp|p=33804308|t=2021. Fibrosis after Myocardial Infarction: An Overview on Cellular Processes, Molecular Pathways, Clinical Evaluation and Prognostic Value.|pdf=|usr=}} {{tp|p=33655986|t=2021. The semantic of a pandemic: Are cardiovascular patients dying "with" or "from" COVID-19? Reflections from a case report.|pdf=|usr=}} {{tp|p=31567942|t=2019. Clinical significance of serum magnesium levels in patients with heart failure with preserved ejection fraction.|pdf=|usr=}} {{tp|p=32587982|t=2020. Renin-angiotensin system blockers and susceptibility to COVID-19: a multinational open science cohort study.|pdf=|usr=}} {{tp|p=33806624|t=2021. SARS-CoV-2 Disease Adjuvant Therapies and Supplements Breakthrough for the Infection Prevention.|pdf=|usr=}} {{tp|p=33837899|t=2021. COVID-19: imbalance of multiple systems during infection and importance of therapeutic choice and dosing of cardiac and anti-coagulant therapies.|pdf=|usr=}} {{tp|p=32356628|t=2020. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19.|pdf=|usr=}} {{tp|p=32356627|t=2020. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.|pdf=|usr=}} {{tp|p=34151392|t=2021. The renin-angiotensin system and specifically angiotensin-converting enzyme 2 as a potential therapeutic target in SARS-CoV-2 infections.|pdf=|usr=}} {{tp|p=32893306|t=2020. COVID-19 Pandemic and Angina Pectoris: What If the Pain Pathway Is Pharmaceutically Modulated?|pdf=|usr=}} {{tp|p=32596035|t=2020. LCZ696 mitigates diabetic-induced nephropathy through inhibiting oxidative stress, NF-kappaB mediated inflammation and glomerulosclerosis in rats.|pdf=|usr=}} {{tp|p=33275999|t=2021. A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor.|pdf=|usr=}} {{tp|p=33687143|t=2021. Between two storms, vasoactive peptides or bradykinin underlie severity of COVID-19?|pdf=|usr=}} {{tp|p=33347477|t=2020. Positive association of angiotensin II receptor blockers, not angiotensin-converting enzyme inhibitors, with an increased vulnerability to SARS-CoV-2 infection in patients hospitalized for suspected COVID-19 pneumonia.|pdf=|usr=}} {{tp|p=33006999|t=2020. In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm.|pdf=|usr=}} {{tp|p=33203679|t=2020. Targeting the renin-angiotensin signaling pathway in COVID-19: Unanswered questions, opportunities, and challenges.|pdf=|usr=}} {{tp|p=33550151|t=2021. Colchicine and SARS-CoV-2: Management of the hyperinflammatory state.|pdf=|usr=}} {{tp|p=32999856|t=2020. Clinical deterioration during neutropenia recovery after G-CSF therapy in patient with COVID-19.|pdf=|usr=}} {{tp|p=32905015|t=2020. Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective.|pdf=|usr=}} {{tp|p=33219294|t=2020. Adverse impact of renin-angiotensin system blockade on the clinical course in hospitalized patients with severe COVID-19: a retrospective cohort study.|pdf=|usr=}} {{tp|p=34035891|t=2021. Renin-angiotensin-aldosterone system blockers and region-specific variations in COVID-19 outcomes: findings from a systematic review and meta-analysis.|pdf=|usr=}} {{tp|p=32553503|t=2020. Drugs acting on renin angiotensin system and use in ill patients with COVID-19.|pdf=|usr=}} {{tp|p=34696334|t=2021. The Cross-Talk between Thrombosis and Inflammatory Storm in Acute and Long-COVID-19: Therapeutic Targets and Clinical Cases.|pdf=|usr=}} {{tp|p=33265982|t=2020. Modeling the Molecular Impact of SARS-CoV-2 Infection on the Renin-Angiotensin System.|pdf=|usr=}} {{tp|p=33877436|t=2021. Pharmacological agents modifying the renin angiotensin and natriuretic peptide systems in COVID-19 patients.|pdf=|usr=}} {{tp|p=33779831|t=2021. The advantages of drug treatment with statins in patients with SARS-CoV-2 infection.|pdf=|usr=}} {{tp|p=32719054|t=2020. Sacubitril, valsartan and SARS-CoV-2.|pdf=|usr=}} {{tp|p=26057694|t=2015. Pre-treatment with LCZ696, an orally active angiotensin receptor neprilysin inhibitor, prevents ischemic brain damage.|pdf=|usr=}} {{tp|p=34075552|t=2021. Sacubitril/Valsartan Decreases Atrial Fibrillation Susceptibility by Inhibiting Angiotensin II-Induced Atrial Fibrosis Through p-Smad2/3, p-JNK, and p-p38 Signaling Pathways.|pdf=|usr=}} {{tp|p=31790054|t=2020. Angiotensin-neprilysin inhibition confers renoprotection in rats with diabetes and hypertension by limiting podocyte injury.|pdf=|usr=}} {{tp|p=27653223|t=2016. Angiotensin Neprilysin Inhibition for Patients With Heart Failure: What If Sacubitril/Valsartan Were a Treatment for Cancer?|pdf=|usr=}} {{tp|p=33786624|t=2021. Sacubitril/valsartan inhibits oxLDLinduced MALAT1 expression, inflammation and apoptosis by suppressing the TLR4/NFkappaB signaling pathway in HUVECs.|pdf=|usr=}} further papers from pmc {{tp|p=29939681|t=2021. Sacubitril/Valsartan|pdf=|usr=}} {{tp|p=33839697|t=2021. LCZ696 ameliorates lipopolysaccharide-induced endothelial injury.|pdf=|usr=}} {{tp|p=32463726|t=2020. Differential effects of low-dose sacubitril and/or valsartan on renal disease in salt-sensitive hypertension.|pdf=|usr=}} {{tp|p=29312499|t=2017. LCZ696 (Sacubitril/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD.|pdf=|usr=}} {{tp|p=33074771|t=2021. Renal Denervation to Treat Heart Failure.|pdf=|usr=}} {{tp|p=33437485|t=2020. Management of Cardiac Sarcoidosis in 2020.|pdf=|usr=}} {{tp|p=31108352|t=2019. The therapeutic impact of entresto on protecting against cardiorenal syndrome-associated renal damage in rats on high protein diet.|pdf=|usr=}} {{tp|p=25778676|t=2015. Degradation of the endothelial glycocalyx in clinical settings: searching for the sheddases.|pdf=|usr=}} {{tp|p=30225980|t=2019. Three-dimensional electron microscopy techniques for unravelling mitochondrial dysfunction in heart failure and identification of new pharmacological targets.|pdf=|usr=}} {{tp|p=26989394|t=2016. Current and Potential Therapeutic Strategies for Hemodynamic Cardiorenal Syndrome.|pdf=|usr=}} {{tp|p=30909895|t=2019. The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat.|pdf=|usr=}} {{tp|p=33708498|t=2021. Pathophysiology of heart failure.|pdf=|usr=}} {{tp|p=32444995|t=2020. Protection of Sacubitril/Valsartan against Pathological Cardiac Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure Overload in Mice.|pdf=|usr=}} {{tp|p=34359886|t=2021. Cardiac Fibrosis and Fibroblasts.|pdf=|usr=}} {{tp|p=32059634|t=2020. Angiotensin Receptor-Neprilysin Inhibitor Therapy Reverses Pulmonary Hypertension in End-Stage Heart Failure Patients Awaiting Transplantation.|pdf=|usr=}} {{tp|p=31707802|t=2019. Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan.|pdf=|usr=}} {{tp|p=33983837|t=2021. Pathophysiology and Therapeutic Approaches to Acute Decompensated Heart Failure.|pdf=|usr=}} {{tp|p=32648130|t=2020. Heart Failure with Preserved Ejection Fraction-a Concise Review.|pdf=|usr=}} {{tp|p=30543176|t=2019. Shock - Classification and Pathophysiological Principles of Therapeutics.|pdf=|usr=}} {{tp|p=32103902|t=2020. Silibinin Augments the Antifibrotic Effect of Valsartan Through Inactivation of TGF-beta1 Signaling in Kidney.|pdf=|usr=}} {{tp|p=32310257|t=2020. GDF15: A Hormone Conveying Somatic Distress to the Brain.|pdf=|usr=}} {{tp|p=33295126|t=2021. Time-sensitive approach in the management of acute heart failure.|pdf=|usr=}} {{tp|p=30837806|t=2019. Potassium binders for the prevention of hyperkalaemia in heart failure patients: implementation issues and future developments.|pdf=|usr=}} {{tp|p=29249907|t=2017. Pharmacological approaches to cardio-renal syndrome: a role for the inodilator levosimendan.|pdf=|usr=}} {{tp|p=30592365|t=2019. Adrenomedullin in heart failure: pathophysiology and therapeutic application.|pdf=|usr=}} {{tp|p=31262190|t=2019. LCZ696, an angiotensin receptor-neprilysin inhibitor, ameliorates diabetic cardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis.|pdf=|usr=}} {{tp|p=31906742|t=2020. Targeting Rho-associated coiled-coil forming protein kinase (ROCK) in cardiovascular fibrosis and stiffening.|pdf=|usr=}} {{tp|p=34447792|t=2021. Hypoxia Inducible Factors as Central Players in the Pathogenesis and Pathophysiology of Cardiovascular Diseases.|pdf=|usr=}} {{tp|p=34409075|t=2021. Heart Failure Syndrome With Preserved Ejection Fraction Is a Metabolic Cluster of Non-resolving Inflammation in Obesity.|pdf=|usr=}} {{tp|p=33969025|t=2021. Rationale for the Use of Pirfenidone in Heart Failure With Preserved Ejection Fraction.|pdf=|usr=}} {{tp|p=34490241|t=2021. Oxidative Stress-Induced Ferroptosis in Cardiovascular Diseases and Epigenetic Mechanisms.|pdf=|usr=}} {{tp|p=33859992|t=2021. Update on the Mechanisms of Tubular Cell Injury in Diabetic Kidney Disease.|pdf=|usr=}} {{tp|p=34135773|t=2021. Protective Renal Effects of Atrial Natriuretic Peptide: Where Are We Now?|pdf=|usr=}} {{tp|p=31749710|t=2019. Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction.|pdf=|usr=}} {{tp|p=30534079|t=2018. Mechanisms and Modulation of Oxidative/Nitrative Stress in Type 4 Cardio-Renal Syndrome and Renal Sarcopenia.|pdf=|usr=}} {{tp|p=30565021|t=2019. Practical guidance on the use of sacubitril/valsartan for heart failure.|pdf=|usr=}} {{tp|p=33957252|t=2021. Sacubitril/valsartan alleviates myocardial fibrosis in diabetic cardiomyopathy rats.|pdf=|usr=}} {{tp|p=27032551|t=2016. Rescue of Heart Failure by Mitochondrial Recovery.|pdf=|usr=}} {{tp|p=29050562|t=2017. Renal Sympathetic Denervation Protects the Failing Heart Via Inhibition of Neprilysin Activity in the Kidney.|pdf=|usr=}} {{tp|p=33615821|t=2021. Revisiting and Implementing the Weber and Ventilatory Functional Classifications in Heart Failure by Cardiopulmonary Imaging Phenotyping.|pdf=|usr=}} {{tp|p=32791029|t=2020. Molecular, Cellular, and Clinical Evidence That Sodium-Glucose Cotransporter 2 Inhibitors Act as Neurohormonal Antagonists When Used for the Treatment of Chronic Heart Failure.|pdf=|usr=}} {{tp|p=29325796|t=2018. LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease.|pdf=|usr=}} {{tp|p=34063477|t=2021. Sympathetic Activation and Arrhythmogenesis after Myocardial Infarction: Where Do We Stand?|pdf=|usr=}} {{tp|p=32870495|t=2021. Renal dysfunction in cardiovascular diseases and its consequences.|pdf=|usr=}} {{tp|p=31924408|t=2020. The angiotensin II receptor-neprilysin inhibitor LCZ696 attenuates the progression of proteinuria in type 2 diabetic rats.|pdf=|usr=}} {{tp|p=31412886|t=2019. Meeting abstracts from the 9th International Conference on cGMP: Generators, Effectors and Therapeutic Implications.|pdf=|usr=}} {{tp|p=28944310|t=2017. Metabolic Origins of Heart Failure.|pdf=|usr=}} {{tp|p=30235455|t=2018. Kidney Response to Heart Failure: Proteomic Analysis of Cardiorenal Syndrome.|pdf=|usr=}} {{tp|p=33777494|t=2021. Anemia of cardiorenal syndrome.|pdf=|usr=}} {{tp|p=30597709|t=2019. Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival.|pdf=|usr=}} {{tp|p=34296299|t=2021. Sacubitril/valsartan (LCZ696) reduces myocardial injury following myocardial infarction by inhibiting NLRP3induced pyroptosis via the TAK1/JNK signaling pathway.|pdf=|usr=}} {{tp|p=32139695|t=2020. Acute heart failure.|pdf=|usr=}} {{tp|p=31073128|t=2019. Dilated cardiomyopathy.|pdf=|usr=}} {{tp|p=34759348|t=2021. Crosstalk between the renin-angiotensin, complement and kallikrein-kinin systems in inflammation.|pdf=|usr=}} {{tp|p=31673162|t=2020. Kidney disease trials for the 21st century: innovations in design and conduct.|pdf=|usr=}} {{tp|p=32739920|t=2020. Proenkephalin: A New Biomarker for Glomerular Filtration Rate and Acute Kidney Injury.|pdf=|usr=}} {{tp|p=33922366|t=2021. Chagas Cardiomyopathy: From Romana Sign to Heart Failure and Sudden Cardiac Death.|pdf=|usr=}} {{tp|p=32747644|t=2020. A novel protective role of sacubitril/valsartan in cyclophosphamide induced lung injury in rats: impact of miRNA-150-3p on NF-kappaB/MAPK signaling trajectories.|pdf=|usr=}} {{tp|p=31019233|t=2019. Neprilysin Inhibitor-Angiotensin II Receptor Blocker Combination Therapy (Sacubitril/valsartan) Suppresses Atherosclerotic Plaque Formation and Inhibits Inflammation in Apolipoprotein E- Deficient Mice.|pdf=|usr=}} {{tp|p=34079271|t=2021. Epigenetic Therapies for Heart Failure: Current Insights and Future Potential.|pdf=|usr=}} {{tp|p=32879702|t=2020. Sympathetic nervous system activation and heart failure: Current state of evidence and the pathophysiology in the light of novel biomarkers.|pdf=|usr=}} {{tp|p=33870733|t=2021. Sacubitril/valsartan treatment has differential effects in modulating diabetic kidney disease in db/db mice and KKAy mice compared with valsartan treatment.|pdf=|usr=}} {{tp|p=27129187|t=2016. Blood pressure-independent renoprotection in diabetic rats treated with AT1 receptor-neprilysin inhibition compared with AT1 receptor blockade alone.|pdf=|usr=}} {{tp|p=32488503|t=2020. Impact of Sacubitril-Valsartan on Markers of Glomerular Function.|pdf=|usr=}} {{tp|p=34216577|t=2021. Sacubitril/valsartan in chronic kidney disease: From pharmacological mechanism to clinical application.|pdf=|usr=}} {{tp|p=33581182|t=2021. Sacubitril-valsartan treatment is associated with decrease in central apneas in patients with heart failure with reduced ejection fraction.|pdf=|usr=}} {{tp|p=33310048|t=2021. Sacubitril/valsartan treatment relieved the progression of established pulmonary hypertension in rat model and its mechanism.|pdf=|usr=}} {{tp|p=23023670|t=2012. Trial watch: dual-acting combination meets heart failure end point.|pdf=|usr=}} {{tp|p=20431556|t=2010. Trial watch: dual inhibition shows promise in hypertension.|pdf=|usr=}} {{tp|p=33541194|t=2021. Inhibition of neprilysin with sacubitril without RAS blockage aggravates renal disease in Dahl SS rats.|pdf=|usr=}}

Zurück zur Seite PHA Sacubitril.